Using EHRs for Real-World Safety Signal Detection in Pharmacovigilance

Published on 22/12/2025

How to Use EHRs for Safety Signal Detection in Real-World Settings

Electronic Health Records (EHRs) offer a powerful avenue for monitoring drug safety in real-world settings. Beyond their role in patient care documentation, EHRs are increasingly being utilized by pharma and clinical research teams for early safety signal detection—a critical function in pharmacovigilance.

This tutorial explores practical steps, tools, and compliance considerations for leveraging EHR data to identify, validate, and respond to safety signals efficiently and accurately.

Table of Contents

What Are Safety Signals and Why Detect Them Early?

A safety signal is a hypothesis-generating alert indicating a possible causal relationship between a drug and an adverse event. Early detection of these signals can help prevent widespread harm, guide regulatory actions, and inform risk mitigation strategies. Traditionally, safety signal detection relied heavily on spontaneous reports, but these are often delayed, incomplete, or underreported.

EHRs, with their longitudinal, structured, and semi-structured data, provide a rich and timely alternative for signal generation. According to USFDA pharmacovigilance guidelines, real-world evidence from EHRs can strengthen the identification of rare or unexpected adverse events.

Steps to Use EHRs for Safety Signal Detection:

Define Your Drug-Event Pair

of Interest:

Start by clearly identifying the drug(s) under surveillance and the adverse event(s) of concern. For example, assessing the signal for hepatic injury in patients using Drug X.

Establish Data Access and Governance:

Partner with healthcare institutions or EHR data aggregators. Ensure ethical approvals and data-sharing agreements are in place. Maintain data de-identification as per HIPAA and pharma regulatory compliance standards.

Extract Relevant Clinical and Administrative Data:

Prescription orders
Diagnosis codes (ICD-10)
Laboratory values
Clinical notes (using NLP)
Patient demographics and vitals

Ensure that your extraction process is consistent with GMP documentation practices for informatics workflows.

Normalize and Clean the Dataset:

Use common data models (CDMs) like OMOP or Sentinel. Standardizing terminologies across datasets is essential to avoid misclassification or duplicate records.

Apply Signal Detection Algorithms:

Disproportionality analysis (e.g., Proportional Reporting Ratio, Empirical Bayes)
Temporal pattern discovery using sequence symmetry analysis
Machine learning models (e.g., logistic regression, gradient boosting) trained on labeled datasets

Practical Considerations for EHR-Based Signal Detection:

While EHRs offer real-time data, several practical issues must be addressed:

Missing or incomplete data: Imputation and statistical controls help mitigate biases.
Confounding factors: Adjust for patient comorbidities, concomitant medications, and lifestyle factors using multivariate analysis.
Outcome misclassification: Cross-verify event codes with clinical narratives using NLP.
Latency of signal emergence: Use time-to-event analysis to understand signal timing post-drug initiation.

Applying these filters improves the reliability of signal detection and supports validation master plans for safety-related analytics platforms.

Case Example: EHR Surveillance for Cardiovascular Risk

In a post-marketing study of a novel anti-diabetic drug, researchers noticed a rise in cardiovascular events within 90 days of treatment start. EHR-based analysis across four large hospital systems revealed a statistically significant increase in myocardial infarction rates. These findings were flagged as a potential safety signal and submitted to regulatory bodies for further evaluation.

Subsequent randomized controlled trials confirmed the association, leading to updated labeling and risk management strategies—demonstrating how EHRs can play a pivotal role in life-saving interventions.

Tools and Platforms for Real-Time Signal Detection:

Consider integrating these technologies for EHR-based pharmacovigilance:

FDA Sentinel Initiative: Designed for active surveillance using healthcare claims and EHRs.
OHDSI’s Atlas: Web-based tool for cohort definition, characterization, and pathway exploration.
AEGIS: An open-source toolkit for adverse event signal mining.
Custom dashboards: Build dashboards using R Shiny or Power BI for visualization and alerting.

When adopting these tools, consider aligning your approach with SOP training pharma practices to ensure consistency and audit readiness.

Regulatory and Ethical Compliance:

Ensure institutional review board (IRB) approval for retrospective and prospective data analysis.
Comply with privacy frameworks such as HIPAA, GDPR, and national clinical data regulations.
Maintain audit trails for data access and transformations to support inspections and publications.

StabilityStudies.in methodologies, originally developed for physical product monitoring, are now being repurposed for temporal pattern tracking in safety data streams.

Best Practices for Success:

Start small: Pilot the methodology on one drug-event pair before scaling up.
Collaborate with informatics teams: They can help configure queries, manage servers, and integrate clinical logic.
Report findings transparently: Even non-significant results can inform future signal strategies.
Continually validate models: Use fresh data batches to confirm findings over time.
Integrate with spontaneous reporting: Combine EHR signals with post-marketing surveillance systems like MedWatch.

Conclusion: A New Era in Drug Safety Monitoring

EHRs are transforming how the pharmaceutical industry approaches safety signal detection. With structured frameworks, advanced analytics, and rigorous compliance, these digital tools can provide earlier, broader, and more actionable insights than ever before.

By implementing the techniques outlined here, pharma professionals can ensure patient safety, satisfy regulatory requirements, and enhance public trust in medical innovation.